Pharmacotherapy of atrial fibrillation

Jan Nemec, Win Kuang Shen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Atrial fibrillation (AF) remains a widespread health problem and the drugs available for its treatment suffer from several drawbacks, including potentially lethal proarrhythmia, serious non-cardiac toxicity and limited efficacy. The evidence for efficacy of currently available anti-arrhythmic agents for sinus rhythm restoration and maintenance is reviewed, with emphasis on randomised trials when available. The current approach to thromboembolism prophylaxis in AF is summarised. 1999

Original languageEnglish (US)
Pages (from-to)81-96
Number of pages16
JournalExpert Opinion on Pharmacotherapy
Volume1
Issue number1
StatePublished - 1999

Fingerprint

Atrial Fibrillation
Drug Therapy
Anti-Arrhythmia Agents
Thromboembolism
Maintenance
Health
Pharmaceutical Preparations
Therapeutics

Keywords

  • Anti-arrhythmic drugs
  • Anticoagiilation
  • Atrial fibrillation
  • Thromboembolism
  • Treatment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Nemec, J., & Shen, W. K. (1999). Pharmacotherapy of atrial fibrillation. Expert Opinion on Pharmacotherapy, 1(1), 81-96.

Pharmacotherapy of atrial fibrillation. / Nemec, Jan; Shen, Win Kuang.

In: Expert Opinion on Pharmacotherapy, Vol. 1, No. 1, 1999, p. 81-96.

Research output: Contribution to journalArticle

Nemec, J & Shen, WK 1999, 'Pharmacotherapy of atrial fibrillation', Expert Opinion on Pharmacotherapy, vol. 1, no. 1, pp. 81-96.
Nemec, Jan ; Shen, Win Kuang. / Pharmacotherapy of atrial fibrillation. In: Expert Opinion on Pharmacotherapy. 1999 ; Vol. 1, No. 1. pp. 81-96.
@article{363e29ba27bf4fa9a20e1da6467f5522,
title = "Pharmacotherapy of atrial fibrillation",
abstract = "Atrial fibrillation (AF) remains a widespread health problem and the drugs available for its treatment suffer from several drawbacks, including potentially lethal proarrhythmia, serious non-cardiac toxicity and limited efficacy. The evidence for efficacy of currently available anti-arrhythmic agents for sinus rhythm restoration and maintenance is reviewed, with emphasis on randomised trials when available. The current approach to thromboembolism prophylaxis in AF is summarised. 1999",
keywords = "Anti-arrhythmic drugs, Anticoagiilation, Atrial fibrillation, Thromboembolism, Treatment",
author = "Jan Nemec and Shen, {Win Kuang}",
year = "1999",
language = "English (US)",
volume = "1",
pages = "81--96",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Pharmacotherapy of atrial fibrillation

AU - Nemec, Jan

AU - Shen, Win Kuang

PY - 1999

Y1 - 1999

N2 - Atrial fibrillation (AF) remains a widespread health problem and the drugs available for its treatment suffer from several drawbacks, including potentially lethal proarrhythmia, serious non-cardiac toxicity and limited efficacy. The evidence for efficacy of currently available anti-arrhythmic agents for sinus rhythm restoration and maintenance is reviewed, with emphasis on randomised trials when available. The current approach to thromboembolism prophylaxis in AF is summarised. 1999

AB - Atrial fibrillation (AF) remains a widespread health problem and the drugs available for its treatment suffer from several drawbacks, including potentially lethal proarrhythmia, serious non-cardiac toxicity and limited efficacy. The evidence for efficacy of currently available anti-arrhythmic agents for sinus rhythm restoration and maintenance is reviewed, with emphasis on randomised trials when available. The current approach to thromboembolism prophylaxis in AF is summarised. 1999

KW - Anti-arrhythmic drugs

KW - Anticoagiilation

KW - Atrial fibrillation

KW - Thromboembolism

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0033224588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033224588&partnerID=8YFLogxK

M3 - Article

C2 - 11249567

AN - SCOPUS:0033224588

VL - 1

SP - 81

EP - 96

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -